MedTrace Logo

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

NCT04172571 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2024-05-30

No results posted yet for this study

Summary

This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody AK105 plus anlotinib hydrochloride in the first-line treatment of patients with unresectable hepatocellular carcinoma.

Conditions

Interventions

BIOLOGICAL

AK105

Anti-PD-1 antibody; IV infusion, 200 mg Q3W

DRUG

Anlotinib Hydrochloride

multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off

Sponsors & Collaborators

  • Akeso Tiancheng, Inc

    collaborator OTHER

  • Akeso

    lead INDUSTRY

Principal Investigators

  • Shunchang Jiao, MD · Chinese PLA General Hospital

  • Li Bai, MD · Chinese PLA General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-22
Primary Completion
2022-06-01
Completion
2022-07-08
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04172571 on ClinicalTrials.gov